Compare FGBI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | ATYR |
|---|---|---|
| Founded | 1934 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 72.6M |
| IPO Year | N/A | 2015 |
| Metric | FGBI | ATYR |
|---|---|---|
| Price | $4.79 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 24.3K | ★ 3.3M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,036,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.20 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.31 | $0.64 |
| 52 Week High | $14.93 | $7.29 |
| Indicator | FGBI | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 47.53 |
| Support Level | $4.31 | $0.70 |
| Resistance Level | $5.17 | $0.86 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 43.44 | 81.60 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.